NY-PHILIP-MORRIS-INTL
A potential tenfold reduction in smoking-attributable deaths is possible if people who currently smoke were to switch to smoke-free products, Jacek Olczak, CEO of Philip Morris International Inc. (PMI) (NYSE: PM) will state in a speech today. He will explain the role smoke-free products can play in ending cigarette smoking globally and the human consequences of inaction.
“For over a decade, PMI has championed a smoke-free future. Having invested more than $10.5 billion to scientifically research, develop, and commercialize smoke-free products—which today account for more than a third of our total net revenues—we are living this future,” says Olczak. “Yet, inexplicably, there are countries stuck in the past where smokers can easily access cigarettes—the most harmful form of nicotine consumption—but not the better option of smoke-free alternatives.”
Using the World Health Organization’s data, estimates, and methodologies, along with other third-party data, PMI calculated the potential public health impact of the world’s smokers switching from cigarettes to less harmful, smoke-free products. The hypothetical model shows that if smoke-free products are assumed to be 80 percent less risky than cigarettes and if people who currently smoke were to switch to them completely, then over their lifetime, there’s a potential for a tenfold reduction in smoking-attributable deaths compared with historical tobacco control measures alone.
In a world that demands change, people are counting on their governments to keep up with technological advancements while ensuring innovations are appropriately regulated. According to a new international survey conducted by independent research firm Povaddo for PMI, more than half of global respondents (56 percent) believe their government needs to consider the role better alternatives such as e-cigarettes and heated tobacco products can play in eradicating cigarette use in their country.
Moreover, 8 in 10 global respondents (82 percent) agree they would be somewhat or very angry, frustrated, or upset to learn that a breakthrough that could help address a societal issue was not made available to the public due to government inaction, and 88 percent agree that public health authorities should fully embrace and seek to learn from evidence and data from other countries.
During a streamed broadcast via Reuters’ (@ReutersPlus) on X (formerly Twitter) today at 10am ET, Olczak explains that, while there are limitations to any hypothetical analysis, real-world examples from countries that accept tobacco harm reduction confirm its positive impact.
Public health data show1, for instance, that Sweden has one of the lowest smoking rates in the developed world, at just 5.8 percent. This is largely due to the availability of snus—a moist oral tobacco product—which Swedish men began switching to decades ago. Today, male mortality rates due to tobacco are much lower in Sweden2 compared with other European Union countries, where snus is banned. Putting that in perspective, the Swedish Snus Commission estimates that more than 350,000 smoking-attributable deaths among men could have been avoided each year if the other EU countries had matched Sweden’s tobacco-related mortality rate.
There is also compelling evidence from Japan. In 2019—five years after heated tobacco products were introduced in that country—independent studies3 showed an unprecedented decline in cigarette sales. The U.K., which has adopted smoke-free products to help adults abandon cigarettes, has also seen smoking rates fall significantly.4
“Innovations become advancements when they address existing issues and offer improvements. Decades ago, our industry was challenged to make cigarettes less harmful. We have delivered, creating science-based alternatives that remove combustion, the primary factor in smoking-related disease,” says Olczak. “It is no longer a case of if smoke-free alternatives are better than cigarette smoking; it is a case of by how much.”
A video of Olczak’s full speech will be accessible here from 10am ET and additional information on PMI’s hypothetical model is available at pmi.com/rethinkdisruption.
Survey Methodology
Povaddo conducted the online survey on behalf of PMI between March 30 and April 20, 2023. The survey was fielded among 30,591 general population adults aged 21 or older in 15 countries: Argentina, Austria, Brazil, Colombia, Dominican Republic, Malaysia, Mexico, Pakistan, Philippines, Serbia, South Africa, South Korea, Tunisia, United Kingdom, and United States. Approximately 2,000 interviews were collected in each country. Data have been weighted by age, gender, and nicotine product use per market to match national statistics. Results are accurate to a margin of error of +/- 1 percent.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General Snus as Modified Risk Tobacco Products (MRTPs). As of June 30, 2023, PMI’s smoke-free products were available for sale in 80 markets, and PMI estimates that approximately 19.4 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 35.4 percent of PMI’s total second-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.
# # #
1 Swedish National Public Health Survey
3 National Health and Nutrition Survey, Japan
4 Smoking Habits in the UK and Constituent Countries, 2021 dataset edition
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919717263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom